Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | GAA | P10253 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | FLT3 | P36888 | 9/20 | 0.71 |
| ▸ | NPC1 | O15118 | 4/20 | 0.71 |
| ▸ | RAB9A | P51151 | 4/20 | 0.71 |
| ▸ | CASP3 | P42574 | 1/20 | 0.67 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.67 |
| ▸ | TLR2 | O60603 | 2/20 | 0.67 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.64 |
| ▸ | CFTR | P13569 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.60 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8290385 | 0.97 | MEN1 (0.74) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL5448370 | 0.93 | MEN1 (0.68) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL5455976 | 0.90 | KMT2A (0.64) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL4234573 | 0.89 | FLT3 (0.72) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL5467902 | 0.88 | FLT3 (0.72) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL5455065 | 0.88 | MEN1 (0.79) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL5462791 | 0.88 | FLT3 (0.72) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL5446174 | 0.87 | FLT3 (0.71) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL18015730 | 0.86 | KCNH2 (0.71) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL5453264 | 0.86 | FLT3 (0.71) | MEN1KMT2AALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | claimed |
| US-9963452-B2 | Methods, compounds, and compositions for inhibition of ROS | AUGUSTA PHARMACEUTICALS INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20160031890-A1 | NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS FOR INHIBITION OF ROS | GRUENEBERG, Dorre A. | 2016-02-04 | — | — | US | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | MEN1 2891/4885KMT2A 4785/4885ALDH1A1 1153/4885 |
| US-20160031890-A1 | NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS FOR INHIBITION OF ROS | ROS1, NOX4, NOX1 | MEN1 4070/4885KMT2A 2243/4885ALDH1A1 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.